Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment

Proteomics

Volumn 14, Issue 16, 2014, Pages 1845-1856

  Choi, Do Young ^a   You, Sungyong ^b   Jung, Jae Hun ^a   Lee, Jae Cheol ^c   Rho, Jin Kyung ^c   Lee, Kye Young ^d   Freeman, Michael R ^b,e,f   Kim, Kwang Pyo ^a   Kim, Jayoung ^b,e,f  

^a Kyung Hee University   (South Korea)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c University of Ulsan College of Medicine   (South Korea)

^d Konkuk University School of Medicine   (South Korea)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AKT; Cell biology; Extracellular vesicles; MTOR signaling pathway; Nonsmall cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEOME; DACTOLISIB; RAPAMYCIN; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; COMPLEX FORMATION; CYTOPLASM VESICLE; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; APOPTOSIS; CANCER CELL; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; DRUG SENSITIZATION; EXOSOME; LIQUID CHROMATOGRAPHY; LUNG CANCER CELL LINE; NON SMALL CELL LUNG CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN PHOSPHORYLATION; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG RESISTANCE; EXTRACELLULAR MATRIX; GENETICS; LUNG; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; POINT MUTATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX; HUMANS; LUNG; LUNG NEOPLASMS; POINT MUTATION; PROTEIN KINASE INHIBITORS; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR MICROENVIRONMENT;

EID: 84905705777     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201400008     Document Type: Article

References (72)

1. D'Souza-Schorey, C., Clancy, J. W., Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev. 2012, 26, 1287-1299.
2. Muralidharan-Chari, V., Clancy, J. W., Sedgwick, A., D'Souza-Schorey, C., Microvesicles: mediators of extracellular communication during cancer progression. J. Cell Sci. 2010, 123, 1603-1611.
3. Hosseini-Beheshti, E., Pham, S., Adomat, H., Li, N., Tomlinson Guns, E. S., Exosomes as biomarker enriched microvesicles: characterization of exosomal proteins derived from a panel of prostate cell lines with distinct AR phenotypes. Mol. Cell. Proteomics 2012, 11, 863-885.
4. Noerholm, M., Balaj, L., Limperg, T., Salehi, A. et al., RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer 2012, 12, 22.
5. Akao, Y., Iio, A., Itoh, T., Noguchi, S. et al., Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol. Ther. 2011, 19, 395-399.
6. Muralidharan-Chari, V., Clancy, J., Plou, C., Romao, M. et al., ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr. Biol. 2009, 19, 1875-1885.
7. Palazzolo, G., Albanese, N. N., G, D. I. C., Gygax, D. et al., Proteomic analysis of exosome-like vesicles derived from breast cancer cells. Anticancer Res. 2012, 32, 847-860.
8. Park, J. E., Tan, H. S., Datta, A., Lai, R. C. et al., Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol. Cell. Proteomics 2010, 9, 1085-1099.
9. Principe, S., Hui, A. B., Bruce, J., Sinha, A. et al., Tumor-derived exosomes and microvesicles in head and neck cancer: implications for tumor biology and biomarker discovery. Proteomics 2013, 13, 1608-1623.
10. Skinner, A. M., O'Neill, S. L., Kurre, P., Cellular microvesicle pathways can be targeted to transfer genetic information between non-immune cells. PloS One 2009, 4, e6219.
11. Grange, C., Tapparo, M., Collino, F., Vitillo, L. et al., Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011, 71, 5346-5356.
12. Choi, D. S., Kim, D. K., Kim, Y. K., Gho, Y. S., Proteomics, transcriptomics and lipidomics of exosomes and ectosomes. Proteomics 2013, 13, 1554-1571.
13. Peinado, H., Lavotshkin, S., Lyden, D., The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Sem. Cancer Biol. 2011, 21, 139-146.
14. Camussi, G., Deregibus, M. C., Bruno, S., Grange, C. et al., Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am. J. Cancer Res. 2011, 1, 98-110.
15. Mrvar-Brecko, A., Sustar, V., Jansa, V., Stukelj, R. et al., Isolated microvesicles from peripheral blood and body fluids as observed by scanning electron microscope. Blood Cells Mol. Dis. 2010, 44, 307-312.
16. Park, J. O., Choi, D. Y., Choi, D. S., Kim, H. J. et al., Identification and characterization of proteins isolated from microvesicles derived from human lung cancer pleural effusions. Proteomics 2013, 13, 2125-2134.
17. Lee, E. Y., Park, K. S., Yoon, Y. J., Lee, J. et al., Therapeutic effects of autologous tumor-derived nanovesicles on melanoma growth and metastasis. PloS One 2012, 7, e33330.
18. Lee, H., Lytton-Jean, A. K., Chen, Y., Love, K. T. et al., Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat. Nanotechnol. 2012, 7, 389-393.
19. Nakayama, T., Butler, J. S., Sehgal, A., Severgnini, M. et al., Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particles. Mol. Ther. 2012, 20, 1582-1589.
20. Mascaux, C., Wynes, M. W., Kato, Y., Tran, C. et al., EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor-a novel antibody for immunohistochemistry or AQUA technology. Clin. Cancer Res. 2011, 17, 7796-7807.
21. Suda, K., Murakami, I., Katayama, T., Tomizawa, K. et al., Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin. Cancer Res. 2010, 16, 5489-5498.
22. Li, T., Kung, H. J., Mack, P. C., Gandara, D. R., Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J. Clin. Oncol. 2013, 31, 1039-1049.
23. Ma, P. C., Personalized targeted therapy in advanced non-small cell lung cancer. Cleve. Clin. J. Med. 2012, 79 (Electronic Suppl 1), eS56-eS60.
24. Brugger, W., Thomas, M., EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment. Lung Cancer 2012, 77, 2-8.
25. Ercan, D., Xu, C., Yanagita, M., Monast, C. S. et al., Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2012, 2, 934-947.
26. Carbone, D. P., Ding, K., Roder, H., Grigorieva, J. et al., Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial. J. Thorac. Oncol. 2012, 7, 1653-1660.
27. Goto, K., Ichinose, Y., Ohe, Y., Yamamoto, N. et al., Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J. Thorac. Oncol. 2012, 7, 115-121.
28. Ellison, G., Zhu, G., Moulis, A., Dearden, S. et al., EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J. Clin. Pathol. 2013, 66, 79-89.
29. Keller, A., Nesvizhskii, A. I., Kolker, E., Aebersold, R., Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 2002, 74, 5383-5392.
30. Nesvizhskii, A. I., Keller, A., Kolker, E., Aebersold, R., A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 2003, 75, 4646-4658.
31. Braisted, J. C., Kuntumalla, S., Vogel, C., Marcotte, E. M. et al., The APEX Quantitative Proteomics Tool: generating protein quantitation estimates from LC-MS/MS proteomics results. BMC Bioinformatics 2008, 9, 529.
32. Bolstad, B. M., Irizarry, R. A., Astrand, M., Speed, T. P., A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19, 185-193.
33. Mueller, L. N., Rinner, O., Schmidt, A., Letarte, S. et al., SuperHirn-a novel tool for high resolution LC-MS-based peptide/protein profiling. Proteomics 2007, 7, 3470-3480.
34. Hwang, D., Rust, A. G., Ramsey, S., Smith, J. J. et al., A data integration methodology for systems biology. Proc. Natl. Acad. Sci. USA 2005, 102, 17296-17301.
35. Storey, J. D., Tibshirani, R., Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. USA 2003, 100, 9440-9445.
36. Huang da, W., Sherman, B. T., Lempicki, R. A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4, 44-57.
37. Lachmann, A., Ma'ayan, A., KEA: kinase enrichment analysis. Bioinformatics 2009, 25, 684-686.
38. Peri, S., Navarro, J. D., Kristiansen, T. Z., Amanchy, R. et al., Human protein reference database as a discovery resource for proteomics. Nucleic Acids Res. 2004, 32, D497-D501.
39. Stark, C., Breitkreutz, B. J., Reguly, T., Boucher, L. et al., BioGRID: a general repository for interaction datasets. Nucleic Acids Res. 2006, 34, D535-D539.
40. von Mering, C., Huynen, M., Jaeggi, D., Schmidt, S. et al., STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003, 31, 258-261.
41. Ogata, H., Goto, S., Sato, K., Fujibuchi, W. et al., KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 1999, 27, 29-34.
42. Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D. et al., Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 2000, 25, 25-29.
43. Kim, J., Kim, W. J., Liu, Z., Loda, M., Freeman, M. R., The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle 2012, 11, 1123-1130.
44. Koizumi, F., Shimoyama, T., Taguchi, F., Saijo, N., Nishio, K., Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int. J. Cancer 2005, 116, 36-44.
45. Ono, M., Hirata, A., Kometani, T., Miyagawa, M. et al., Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol. Cancer Ther. 2004, 3, 465-472.
46. Yoshida, T., Okamoto, I., Okamoto, W., Hatashita, E. et al., Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Sci. 2010, 101, 167-172.
47. Cortot, A. B., Repellin, C. E., Shimamura, T., Capelletti, M. et al., Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res. 2013, 73, 834-843.
48. Lu, P., Vogel, C., Wang, R., Yao, X., Marcotte, E. M., Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation. Nat. Biotechnol. 2007, 25, 117-124.
49. Herrera, V. A., Zeindl-Eberhart, E., Jung, A., Huber, R. M., Bergner, A., The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines. Anticancer Res. 2011, 31, 849-854.
50. Nyfeler, B., Chen, Y., Li, X., Pinzon-Ortiz, M. et al., RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth. PloS One 2012, 7, e48548.
51. Xie, H., Lee, M. H., Zhu, F., Reddy, K. et al., Discovery of the novel mTOR inhibitor and its antitumor activities in vitro and in vivo. Mol. Cancer Ther. 2013, 12, 950-958.
52. Gadgeel, S. M., Wozniak, A., Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clin. Lung Cancer 2013, 14, 322-332.
53. Sinha, A., Ignatchenko, V., Ignatchenko, A., Mejia-Guerrero, S., Kislinger, T., In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome. Biochem. Biophy. Res. Comm. 2014, 445, 694-701.
54. Lombardi, G., Zustovich, F., Nicoletto, M. O., Donach, M. et al., Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches. Am. J. Clin. Oncol. 2010, 33, 420-423.
55. Sahn, S. A., Pleural effusion in lung cancer. Clin. Chest Med. 1993, 14, 189-200.
56. Musani, A. I., Treatment options for malignant pleural effusion. Curr. Opin. Pulm. Med. 2009, 15, 380-387.
57. Yoneda, K. Y., Mathur, P. N., Gasparini, S., The evolving role of interventional pulmonary in the interdisciplinary approach to the staging and management of lung cancer. Part III: diagnosis and management of malignant pleural effusions. Clin. Lung Cancer 2007, 8, 535-547.
58. Wang, C. L., Wang, C. I., Liao, P. C., Chen, C. D. et al., Discovery of retinoblastoma-associated binding protein 46 as a novel prognostic marker for distant metastasis in nonsmall cell lung cancer by combined analysis of cancer cell secretome and pleural effusion proteome. J. Proteome Res. 2009, 8, 4428-4440.
59. Matsumori, Y., Yano, S., Goto, H., Nakataki, E. et al., ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol. Res. 2006, 16, 15-26.
60. Economidou, F., Margaritopoulos, G., Antoniou, K. M., Siafakas, N. M., The angiogenetic pathway in malignant pleural effusions: pathogenetic and therapeutic implications. Exp. Ther. Med. 2010, 1, 3-7.
61. Yu, C. J., Wang, C. L., Wang, C. I., Chen, C. D. et al., Comprehensive proteome analysis of malignant pleural effusion for lung cancer biomarker discovery by using multidimensional protein identification technology. J. Proteome Res. 2011, 10, 4671-4682.
62. Soltermann, A., Ossola, R., Kilgus-Hawelski, S., von Eckardstein, A. et al., N-glycoprotein profiling of lung adenocarcinoma pleural effusions by shotgun proteomics. Cancer 2008, 114, 124-133.
63. Suda, K., Onozato, R., Yatabe, Y., Mitsudomi, T., EGFR T790M mutation: a double role in lung cancer cell survival? J. Thorac. Oncol. 2009, 4, 1-4.
64. Sharma, S. V., Bell, D. W., Settleman, J., Haber, D. A., Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 2007, 7, 169-181.
65. Inukai, M., Toyooka, S., Ito, S., Asano, H. et al., Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 2006, 66, 7854-7858.
66. Ito, K., Oizumi, S., Fukumoto, S., Harada, M. et al., Clinical characteristics of pleomorphic carcinoma of the lung. Lung Cancer 2010, 68, 204-210.
67. Su, H., Bodenstein, C., Dumont, R. A., Seimbille, Y. et al., Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin. Cancer Res. 2006, 12, 5659-5667.
68. Cappuzzo, F., Toschi, L., Tallini, G., Ceresoli, G. L. et al., Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann. Oncol. 2006, 17, 1120-1127.
69. Fidler, M. J., Basu, S., Buckingham, L., Walters, K. et al., Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res. 2012, 32, 1705-1710.
70. Bae, Y. K., Sung, J. Y., Kim, Y. N., Kim, S. et al., An in vivo C. elegans model system for screening EGFR-inhibiting anti-cancer drugs. PloS One 2012, 7, e42441.
71. Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K. et al., Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res. 2006, 12, 5764-5769.
72. Fleitas, T., Martinez-Sales, V., Vila, V., Reganon, E. et al., Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer. PloS One 2012, 7, e47365.